Nursing Innovation, Leadership, and Dedication Shine During Pandemic

Nursing Innovation, Leadership, and Dedication Shine During Pandemic

It now seems providential that the World Health Organization named 2020 the Year of the Nurse and Midwife to honor Florence Nightingale’s 200th birthday. Who could have predicted how the world would rely on nurses to change the course of the COVID-19 coronavirus pandemic by upholding Nightingale’s leadership and principles of infection control from the 19th century?

Unique Roles in Oncology Nursing: Oncology Nurse Navigation

Unique Roles in Oncology Nursing: Oncology Nurse Navigation

As early detection, treatment modalities, and symptom management advance in oncology care, we are seeing an increase in the number of adult and childhood cancer survivors. Added to the unique challenges of comorbid conditions in an aging population, oncology nurses have a lot to juggle in the spectrum of patient care. The relatively new role of the oncology nurse navigator was developed to enhance care coordination in patients with cancer.

A Perspective on COVID-19 for New and Student Nurses

A Perspective on COVID-19 for New and Student Nurses

COVID-19 coronavirus’s ripple effects extend so far beyond health and health care. Life in the United States doesn’t look the same as it did a few months ago. We’re all affected in some way, but senior nursing students have a distinct set of circumstances related to the pandemic.

FDA Approves New Dosing Regimen for Pembrolizumab

FDA Approves New Dosing Regimen for Pembrolizumab

FDA Approves Niraparib for First-Line Maintenance of Advanced Ovarian Cancer

FDA Approves Niraparib for First-Line Maintenance of Advanced Ovarian Cancer

On April 29, 2020, the U.S. Food and Drug Administration (FDA) approved niraparib (Zejula®) for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy. 

New NCI Initiative Boosts CAR T-Cell Therapy Research

New NCI Initiative Boosts CAR T-Cell Therapy Research

While the world is in the throes of the COVID-19 coronavirus pandemic, cancer research marshals forward with a focus on CAR T-cell therapy. 

NIH Announces Research Strategy for COVID-19

NIH Announces Research Strategy for COVID-19

From international guidelines to economic stimulus and legislative support, the COVID-19 coronavirus pandemic is now global leaders’ top priority. Leading the research efforts is the National Institutes for Health’s (NIH) National Institute of Allergy and Infectious Disease (NIAID). As NIAID’s director for more than 30 years, Anthony Fauci, MD is one of the few, regular faces associated with COVID-19 in the United States. On April 23, 2020, the agency announced that it will spearhead a strategic plan to research a vaccine for COVID-19. 

The Evidence for Herbal Supplements for Immunity and Stress During COVID-19

The Evidence for Herbal Supplements for Immunity and Stress During COVID-19

As the world embarks on unprecedented research efforts to prevent and treat the COVID-19 coronavirus, patients with cancer and healthcare providers alike may be interested in using herbal products to boost their immune system or relieve anxiety and stress. However, finding accurate information is challenging: no herbs have been scientifically proven to prevent or treat COVID-19, and some may even cause harm.

Oncology Drug Reference Sheet: Daratumumab

Oncology Drug Reference Sheet: Daratumumab

Daratumumab (Darzalex®) was originally approved by the U.S. Food and Drug Administration in 2015 with additional indications added since. The most recent new indication was approved in September 2019 for newly diagnosed patients with multiple myeloma who are eligible for autologous stem cell transplantation. In May 2020, daratumumab and hyaluronidase-fihj (Darzalex Faspro™), a subcutaneous (SQ) formulation, was approved.

House Tells FDA to Ban E-Cigarettes During COVID-19

House Tells FDA to Ban E-Cigarettes During COVID-19

On April 1, 2020, the U.S. House of Representatives Subcommittee on Economic and Consumer Policy asked the U.S. Food and Drug Administration (FDA) to clear the market of e-cigarettes because of the COVID-19 coronavirus pandemic. It was responding to FDA’s request to give e-cigarette manufacturers four additional months to submit applications to stay on the market before enforcing a ban.